

# MALATTIE MUSCOLO-SCHELETRICHE TERAPIA INTEGRATA, PERSONALIZZATA E QUALITÀ DI VITA ROMA 6 - 7 ottobre 2023

#### **GISMO**

Gruppo Italiano Studio malattie Metabolismo Osseo

- Osteoporosi
- Malattie Muscolo-Scheletriche
- Malattie Metaboliche
- Dolore
- Nutrizione



Patrizia D'Amelio




Centre Hospitalier Universitaire Vaudoise – UNIL- Lausanne



La fragilità ossea del soggetto anziano: fisiologia o patologia?

## Aging world




In 2050, 1 person out of 3 will be older than 65 years







#### Osteoporosis: is it a disease or normal aging?



# Fractures incidence increases with aging



### Consequences of fractures





**80%** 

After a fracture cannot climb the stairs


#### **HIGH MORTALITY RATE**

**30%** 

Within a year of hip fracture

50%

**Loose independence** 



Treatment is appropriate if the expected benefit outweighs the risk to which we expose the patient.


## Which patient needs treatment?







Trage set for diagnost it use k = 1,145,40 = 51.4 101 x 99 NECK: 46 x 13



#### Scan Information:

Sca n Type: a Left Hip Analysis: Left Hip

#### **DXA Results Summary:**

| Region | Area  | BMC   | BMD   | T-   | Z-   |
|--------|-------|-------|-------|------|------|
| Neck   | 4.75  | 2.36  | 0.496 | 3.2  | -1.2 |
| Truck  | 10,73 | 5.05  | 0.470 | -2.3 | -0.8 |
| Inter  | 17.08 | 12,47 | 0.731 | -2.4 | -0.9 |
| Total  | 32.56 | 19.88 | 0.610 | -2.7 | -1.0 |

THE BMD CV 1.0%, ACT = 1.008, BCF = 1.011, TH = 4.829

WHO Classification: Osteoporosia


### Which patient needs treatment?





- Age 75
- Menopause at 48
- BMD femoral neck -3.2 SD
- BMI: 24
- Does not smoke or drink
- Does not take glucocorticoids
- No history of autoimmune disease
- No other comorbidities

#### Which patient needs treatment?



Mrs D.

- Never fractured
- No family history of femur fracture



#### Mrs F.

- Left wrist fracture at age 65
- Madame's mother fractured her femur at age 73

#### Mrs D.



#### Outil de Calcul

Veuillez répondre aux questions ci-dessous pour calculer la probabilité de fracture sur 10 ans sans or avec DMO




https://frax.shef.ac.uk/FRAX/tool.aspx?lang=fr

#### Mrs F.





#### **Outil de Calcul**

Veuillez répondre aux questions ci-dessous pour calculer la probabilité de fracture sur 10 ans sans ou avec DMO



#### What is the risk threshold for intervention?





#### Madame C



- Age 85
- Menopause at 48
- BMI: 24
- BMD femoral neck -3.2 SD
- Vertebral fracture aged 74
- Mrs.C's mother fractured her femur at age 73
- Does not smoke or drink
- Does not take glucocorticoids
- No history of autoimmune disease

#### Madame C



- Mild, uninvestigated neurocognitive disorders (CDR1)
- Type 2 diabetes
- Parkinson's disease
- ADL: 5/6 (toileting, dressing, WC, transfers, continence, eating)
- IADL: 4/8 (telephone, shopping, meals, housework, laundry, transport, medication, budget)


#### Madame C: estimation of fracture risk



#### **Outil de Calcul**


Veuillez répondre aux questions ci-dessous pour calculer la probabilité de fracture sur 10 ans sans ou avec DMO

| Pays: Royaume-Uni  | Nom/Identité:                      | A propos des facti  | eurs de risques                       |
|--|------------------------------------|---|---------------------------------------|
| Questionnaire:  1. Âge (entre 40 et 90 ans) ou Date de Age:                            |                                    | Acool trois unités par jour ou plus  12. DMO du Col Fémoral (g/cm²) | Non ● Oui<br>Non ○ Oui<br>score: -3.0 |
| Taille (cm)     Fracture antérieure     Parents ayant eu une fracture                  | 165<br>○ Non                       | BMI: 23.9 The ten year probability of fracture (%) with BMD         |                                       |
| de la hanche.  7. Actuellement Fumeur  8. Glucocorticoïdes  9. Polyarthrite rhumatoide | Non Oui  Non Oui  Non Oui  Non Oui | Major osteoporotic Hip Fracture View NOGG Guidance                  | 53                                    |
|  |                                    | If you have a TBS value, click here: Adjus                          | t with TBS                            |



#### Madame C

September 2020: Left femoral neck fracture treated with hip prosthesis





#### Madame C: la suite

-from 01.31 to 05.10.2021: 3 episodes of hip prosthesis dislocation

# December 2021 entry into geriatric care







# Madame C: at hospital discharge



- ADL: 1/6 (toileting, dressing, WC, transfers, continence, eating)
- Mini GDS: 3/4
- MMSE 18/30
- CDR 2


# Meta-analysis of the effect of antiresorptive agents on vertebral fracture risk reduction in patients aged ≥75 years.

| Study name            | <u>Drug</u>      | Statistics for each study |                |                |         |         | Events/total       |           |      |                |        |                   |     |                    |
|-----------------------|------------------|---------------------------|----------------|----------------|---------|---------|--------------------|-----------|------|----------------|--------|-------------------|-----|--------------------|
|                       |                  | Risk<br>ratio             | Lower<br>limit | Upper<br>limit | Z-value | p-value | Treatment          | Control   | F    | Risk ra        | tio ar | nd 95% C          | 1   | Relative<br>weight |
| Ensrud et al., 1997   | Alendronate      | 0.625                     | 0.411          | 0.951          | -2.194  | 0.028   | 30/264             | 50/275    |      |                | -      |                   |     | 24.43              |
| Eastell et al., 2009  | Zoledronate      | 0.401                     | 0.294          | 0.547          | -5.760  | 0.000   | 52/1,083           | 129/1,078 |      |                |        |                   |     | 44.63              |
| McClung et al., 2012  | Denosumab        | 0.364                     | 0.251          | 0.529          | -5.301  | 0.000   | 36/1,155           | 98/1,146  |      |                | -      |                   |     | 30.94              |
|                       |                  | 0.434                     | 0.353          | 0.534          | -7.881  | 0.000   | Server and reserve |           |      |                | •      |                   |     |                    |
| Heterogeneity: Q = 3. | 98, df(Q) = 2, p | = 0.14, /                 | 2 = 49.7       | 9%             |         |         |                    |           | 0.01 | 0.1            | 1      | 10                | 100 |                    |
|                       |                  |                           |                |                |         |         |                    |           |      | Favor<br>eatme |        | Favors<br>control | 200 |                    |

# Meta-analysis of the effect of antiresorptive agents on reducing the risk of femur fracture in patients aged ≥75 years


| Study name            | Drug             | Statistics for each study |                |                |         |         | Events/total |          |        |         |        |                   |     |                    |
|-----------------------|------------------|---------------------------|----------------|----------------|---------|---------|--------------|----------|--------|---------|--------|-------------------|-----|--------------------|
|                       |                  | Risk<br>ratio             | Lower<br>limit | Upper<br>limit | Z-value | p-value | Treatment    | Control  | -<br>F | Risk ra | tio ar | nd 95% C          | 1   | Relative<br>weight |
| McClung et al., 2001  | Risedronate      | 0.854                     | 0.603          | 1.209          | -0.890  | 0.373   | 82/2,573     | 49/1,313 | á      |         |        |                   |     | 55.99              |
| Eastell et al., 2009  | Zoledronate      | 0.771                     | 0.484          | 1.229          | -1.094  | 0.274   | 31/1,497     | 39/1,452 |        |         | -      |                   |     | 31.14              |
| Boonen et al., 2011   | Denosumab        | 0.385                     | 0.186          | 0.795          | -2.581  | 0.010   | 10/1,235     | 26/1,236 |        | 222     | •      |                   |     | 12.87              |
|                       |                  | 0.747                     | 0.576          | 0.968          | -2.202  | 0.028   |              |          |        |         | •      |                   |     |                    |
| Heterogeneity: Q = 3. | 80, df(Q) = 2, p | = 0.15, /                 | 2 = 47.3       | 6%             |         |         |              |          | 0.01   | 0.1     | 1      | 10                | 100 |                    |
|                       |                  |                           |                |                |         |         |              |          | tr     | Favor   | S      | Favors<br>control |     |                    |

# Efficacité dans le « real world » du traitement de l'ostéoporose chez les personnes les plus âgées



Ca/vD

#### Cost-effectiveness of an intervention to prevent secondary fractures



incremental cost-effectiveness value (ICER)

Nayak S, Singer A, Greenspan SL. J Am Geriatr Soc. 2021

# Take home messages

✓ Patients at high risk of fracture should be prescribed antiosteoporotic treatment

